Updates on the Management of Later Relapses of Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

S. Rubinstein

CAR-T in MM: Best Practices in Patient Selection, Treatment, and Mul…

Icahn School of Medicine at Mount Sinai

A. Rossi

Experts Discuss How They Plan to Use CAR-T in Myeloma After First Re…

MyCancerHaven

R. Vij, A. Abdallah

UChicago Medicine Best of ASCO® 2024: Myeloma

UChicago Medicine Annual Practice Updates in Hematology and Oncology

J. Cooperrider

Real-World Experience With Ide-Cel in R/R MM

Donna Reece

Practical Perspectives on Recent CAR-T FDA Approvals in Myeloma

City of Hope

M. Janakiram

Early Line CAR-Ts in Myeloma - Updates and Future Directions

Krina Patel

BCMA & Beyond: Novel Targets for Immunotherapy in MM

Rush University Medical Center

B. Derman

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

CAR-T vs. Bispecific Antibodies in R/R MM: Insights and Future Direc…

Rush University Medical Center

A. Suvannasankha

CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…

Samer Al Hadidi

Managing Infectious Complications With Bispecific and CAR-T Therapy …

SOHO Brazil 2024

N. S. Raje

Experts Discuss Current Approaches in Triple Class Refractory MM

MyCancerHaven

R. Vij, J. Zonder, J. Richter

ASCO® 2024 Insights: "Sequencing Immunotherapy for Myeloma"

2024 ASCO® Annual Meeting Insights Hub

S. Parekh

CAR T-Cells in Multiple Myeloma in 2024

Dana-Farber Cancer Institute

A. Sperling

CAR T-Cell Therapies for Pts With R/R Myeloma: Updates From the Real…

Moffitt Cancer Center

D. Hansen

Future of Novel Next Generation Therapy in the Management of R/R MM

Dana-Farber Cancer Institute

P. Richardson

ASCO® 2024 Insights: "MRD2STOP Study - Discontinuation of Maintenanc…

2024 ASCO® Annual Meeting Insights Hub

B. Derman

Multiple Myeloma: Experts Discuss How to Choose Between CAR-Ts and B…

MyCancerHaven

R. Vij, N. Nathwani

Multiple Myeloma: What You Need to Know About New FDA Approvals of C…

Moffitt Cancer Center

D. Hansen

Multiple Myeloma: CAR T-Cells and Bispecifics - A Case for Moving Th…

UChicago Medicine

N. Raje

2024 Updates in MM: The Role of Immunotherapy

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

A. Cohen

How I Treat R/R MM With CAR-T and Bispecific Antibodies

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

C. Cerchione

Triple-Class-Exposed R/R MM: Results From the KarMMa-3 Trial of Ide-…

Insights from 2023 ASH Annual Meeting

K. Patel

Multiple Myeloma: Adverse Effects of CAR-T

Icahn School of Medicine at Mount Sinai

S. Rajeeve